Q2 EPS Forecast for Corcept Therapeutics Lowered by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at HC Wainwright lowered their Q2 2025 earnings estimates for Corcept Therapeutics in a report released on Tuesday, May 6th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will earn $0.08 per share for the quarter, down from their prior forecast of $0.47. HC Wainwright currently has a “Buy” rating and a $145.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.32 EPS, Q4 2025 earnings at $0.70 EPS, FY2025 earnings at $1.29 EPS, FY2026 earnings at $3.56 EPS, FY2027 earnings at $7.33 EPS, FY2028 earnings at $10.47 EPS and FY2029 earnings at $12.96 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Monday, May 5th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.17. Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The company had revenue of $157.21 million during the quarter, compared to the consensus estimate of $177.93 million. During the same quarter in the prior year, the firm earned $0.25 EPS. The company’s revenue was up 7.1% compared to the same quarter last year.

CORT has been the topic of several other reports. StockNews.com raised Corcept Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday. Truist Financial set a $135.00 price objective on Corcept Therapeutics in a report on Tuesday. Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $130.00 to $142.00 and gave the company a “buy” rating in a research note on Tuesday, April 1st. Finally, Piper Sandler increased their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the stock an “overweight” rating in a research note on Thursday, April 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $138.25.

Corcept Therapeutics Price Performance

Shares of NASDAQ:CORT opened at $70.23 on Thursday. The firm has a market cap of $7.45 billion, a price-to-earnings ratio of 55.74 and a beta of 0.22. Corcept Therapeutics has a 1 year low of $26.53 and a 1 year high of $117.33. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The business has a fifty day simple moving average of $66.86 and a 200 day simple moving average of $60.78.

Hedge Funds Weigh In On Corcept Therapeutics

A number of institutional investors have recently made changes to their positions in CORT. Black Diamond Financial LLC grew its holdings in Corcept Therapeutics by 4.0% in the 4th quarter. Black Diamond Financial LLC now owns 5,200 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 200 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in shares of Corcept Therapeutics by 3.0% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 7,954 shares of the biotechnology company’s stock valued at $909,000 after acquiring an additional 230 shares during the period. Quadrant Capital Group LLC grew its stake in shares of Corcept Therapeutics by 9.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,969 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 257 shares during the last quarter. Summit Investment Advisors Inc. increased its position in Corcept Therapeutics by 3.3% during the fourth quarter. Summit Investment Advisors Inc. now owns 8,459 shares of the biotechnology company’s stock worth $426,000 after acquiring an additional 268 shares during the period. Finally, Arizona State Retirement System raised its stake in Corcept Therapeutics by 1.1% during the 4th quarter. Arizona State Retirement System now owns 27,270 shares of the biotechnology company’s stock valued at $1,374,000 after purchasing an additional 289 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, CEO Joseph K. Belanoff sold 2,924 shares of Corcept Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $60.91, for a total value of $178,100.84. Following the transaction, the chief executive officer now owns 3,019,411 shares in the company, valued at $183,912,324.01. This trade represents a 0.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider William Guyer sold 7,060 shares of the business’s stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $74.31, for a total transaction of $524,628.60. Following the transaction, the insider now directly owns 5,487 shares of the company’s stock, valued at approximately $407,738.97. This represents a 56.27 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 236,738 shares of company stock worth $20,476,238. 20.80% of the stock is currently owned by insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.